Docetaxel addition improves prostate cancer QoL
medwireNews: Adding docetaxel to standard hormonal therapy improves the quality of life (QoL) of men with previously untreated nonmetastatic or metastatic prostate cancer, indicates an analysis of the STAMPEDE trial.
Nicholas James (University of Birmingham, UK), who presented the findings at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA, told the press: “We already knew that docetaxel prolongs survival for men with metastatic prostate cancer, but this improvement in quality of life […] in non-metastatic disease is somewhat surprising.”
Among men with metastatic (M1) disease, addition of six cycles of docetaxel 75 mg/m2 every 3 weeks plus prednisolone 10 mg/day to standard of care hormonal therapy was estimated to prolong survival by 0.89 years and quality-adjusted life–years by 0.51 years. The corresponding estimates for patients with nonmetastatic (M0) disease were 0.78 and 0.39 years, where the latter was driven primarily by the benefits associated with delayed and reduced relapse.
And docetaxel was found to be cost-effective both in M1 and M0 patients, say James et al, adding that “[c]linicians should consider whether the evidence is now sufficiently compelling to support docetaxel use in non-metastatic patients.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group